Our Annual Report and Financial Statement 2021

annual report and financial statement.jpg

Annual and Financial Reports 2021

We are delighted to present the organisation’s 2021 Annual Report and audited accounts. Despite disruptions caused by the global COVID-19 pandemic, PVRI has succeeded in connecting the PH community across the globe and achieved a great deal throughout the year in a transition to a more digital delivery of our mission.

Annual report

Financial statement

Sign up for news

Email address*

The PVRI requests your permission to record and use the personal information provided.

We will use your data to add you to the ‘Membership Directory’ to enable networking amongst like-minded professionals and achieve the wider goals of the PVRI, in line with our ‘Membership Agreement’ and ‘Legitimate Interests’. This directory is accessible only by other members and employees of the PVRI. Some data processing is carried out by third party suppliers, details of which can be found in our ‘Privacy Notice’ .

You can refuse or withdraw your consent at any time without detriment to your membership. You can do this by emailing admin@pvrinstitute.org.

If the purpose for which we wish to use your data or the way in which we use personal data change, we will contact you to renew consent.

Please tick here to confirm your consent to the activities listed above.

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI

Annual and Financial Reports 2021

Related Content

{{GlobalController.truncateTitle("This week in PVD", 65)}}

{{GlobalController.truncateTitle("Sponsored: Pulmonary Arterial Hypertension clinical trial", 65)}}

{{GlobalController.truncateTitle("Our next Drug Discovery and Development Symposium in Bethesda, USA", 65)}}

{{GlobalController.truncateTitle("The Paul Corris International Clinical Research Training Scholarship at Newcastle University", 65)}}

{{GlobalController.truncateTitle("Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension", 65)}}

Add to reading list

Share this content

Our research platform is the world.